Genetically increased antioxidative protection and decreased chronic obstructive pulmonary disease

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Genetically increased antioxidative protection and decreased chronic obstructive pulmonary disease. / Juul, Klaus; Tybjærg-Hansen, Anne; Marklund, Stefan; Lange, Peter; Nordestgaard, Børge G.; Tybjærg-Hansen, Anne.

I: American Journal of Respiratory and Critical Care Medicine, Bind 173, Nr. 8, 2006, s. 858-64.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Juul, K, Tybjærg-Hansen, A, Marklund, S, Lange, P, Nordestgaard, BG & Tybjærg-Hansen, A 2006, 'Genetically increased antioxidative protection and decreased chronic obstructive pulmonary disease', American Journal of Respiratory and Critical Care Medicine, bind 173, nr. 8, s. 858-64. <http://ajrccm.atsjournals.org/cgi/content/full/173/8/858>

APA

Juul, K., Tybjærg-Hansen, A., Marklund, S., Lange, P., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2006). Genetically increased antioxidative protection and decreased chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine, 173(8), 858-64. http://ajrccm.atsjournals.org/cgi/content/full/173/8/858

Vancouver

Juul K, Tybjærg-Hansen A, Marklund S, Lange P, Nordestgaard BG, Tybjærg-Hansen A. Genetically increased antioxidative protection and decreased chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine. 2006;173(8):858-64.

Author

Juul, Klaus ; Tybjærg-Hansen, Anne ; Marklund, Stefan ; Lange, Peter ; Nordestgaard, Børge G. ; Tybjærg-Hansen, Anne. / Genetically increased antioxidative protection and decreased chronic obstructive pulmonary disease. I: American Journal of Respiratory and Critical Care Medicine. 2006 ; Bind 173, Nr. 8. s. 858-64.

Bibtex

@article{208ccf96c4ba4f48afa21263ca70773d,
title = "Genetically increased antioxidative protection and decreased chronic obstructive pulmonary disease",
abstract = "RATIONALE: Increased oxidative stress is involved in chronic obstructive pulmonary disease (COPD); however, plasma and bronchial lining fluid contains the antioxidant extracellular superoxide dismutase. Approximately 2% of white individuals carry the R213G polymorphism in the gene encoding extracellular superoxide dismutase, which increases plasma extracellular superoxide dismutase 10-fold and presumably also renders bronchial lining fluid high in extracellular superoxide dismutase. OBJECTIVE: We tested the hypothesis that R213G reduces the risk of COPD. METHODS: We studied cross-sectionally and prospectively (during 24 yr) 9,258 individuals from the Danish general population genotyped for R213G. MEASUREMENTS: We determined plasma extracellular superoxide dismutase concentration, pulmonary function and COPD diagnosed by means of spirometry or through national hospitalization and death registers. MAIN RESULTS: In the general population, 97.5% were noncarriers, 2.4% were heterozygotes, and 0.02% were homozygotes. Among R213G noncarriers, extracellular superoxide dismutase plasma concentration was 148+/-52 and 142+/-43 ng/ml (mean+/-SD) in individuals with and without COPD (Student's t test, p=0.02). Among heterozygotes, corresponding concentrations were 1,665+/-498 ng/ml and 1,256+/-379 (p<0.001). The adjusted odds ratio for spirometrically diagnosed COPD in heterozygotes versus noncarriers was 0.5 (95% confidence interval: 0.3-0.9). After stratification, the equivalent adjusted odds ratio was 1.5 (0.3-6.6) among nonsmokers and 0.4 (0.2-0.8) among smokers (p value for interaction=0.10). The adjusted hazard ratio for COPD hospitalization or death during follow-up in heterozygotes versus noncarriers was 0.3 (0.1-0.8). CONCLUSIONS: Extracellular superoxide dismutase R213G heterozygosity protects against development of COPD in the Danish general population. This was observed in smokers, but not in nonsmokers.",
author = "Klaus Juul and Anne Tybj{\ae}rg-Hansen and Stefan Marklund and Peter Lange and Nordestgaard, {B{\o}rge G.} and Anne Tybj{\ae}rg-Hansen",
year = "2006",
language = "English",
volume = "173",
pages = "858--64",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "8",

}

RIS

TY - JOUR

T1 - Genetically increased antioxidative protection and decreased chronic obstructive pulmonary disease

AU - Juul, Klaus

AU - Tybjærg-Hansen, Anne

AU - Marklund, Stefan

AU - Lange, Peter

AU - Nordestgaard, Børge G.

AU - Tybjærg-Hansen, Anne

PY - 2006

Y1 - 2006

N2 - RATIONALE: Increased oxidative stress is involved in chronic obstructive pulmonary disease (COPD); however, plasma and bronchial lining fluid contains the antioxidant extracellular superoxide dismutase. Approximately 2% of white individuals carry the R213G polymorphism in the gene encoding extracellular superoxide dismutase, which increases plasma extracellular superoxide dismutase 10-fold and presumably also renders bronchial lining fluid high in extracellular superoxide dismutase. OBJECTIVE: We tested the hypothesis that R213G reduces the risk of COPD. METHODS: We studied cross-sectionally and prospectively (during 24 yr) 9,258 individuals from the Danish general population genotyped for R213G. MEASUREMENTS: We determined plasma extracellular superoxide dismutase concentration, pulmonary function and COPD diagnosed by means of spirometry or through national hospitalization and death registers. MAIN RESULTS: In the general population, 97.5% were noncarriers, 2.4% were heterozygotes, and 0.02% were homozygotes. Among R213G noncarriers, extracellular superoxide dismutase plasma concentration was 148+/-52 and 142+/-43 ng/ml (mean+/-SD) in individuals with and without COPD (Student's t test, p=0.02). Among heterozygotes, corresponding concentrations were 1,665+/-498 ng/ml and 1,256+/-379 (p<0.001). The adjusted odds ratio for spirometrically diagnosed COPD in heterozygotes versus noncarriers was 0.5 (95% confidence interval: 0.3-0.9). After stratification, the equivalent adjusted odds ratio was 1.5 (0.3-6.6) among nonsmokers and 0.4 (0.2-0.8) among smokers (p value for interaction=0.10). The adjusted hazard ratio for COPD hospitalization or death during follow-up in heterozygotes versus noncarriers was 0.3 (0.1-0.8). CONCLUSIONS: Extracellular superoxide dismutase R213G heterozygosity protects against development of COPD in the Danish general population. This was observed in smokers, but not in nonsmokers.

AB - RATIONALE: Increased oxidative stress is involved in chronic obstructive pulmonary disease (COPD); however, plasma and bronchial lining fluid contains the antioxidant extracellular superoxide dismutase. Approximately 2% of white individuals carry the R213G polymorphism in the gene encoding extracellular superoxide dismutase, which increases plasma extracellular superoxide dismutase 10-fold and presumably also renders bronchial lining fluid high in extracellular superoxide dismutase. OBJECTIVE: We tested the hypothesis that R213G reduces the risk of COPD. METHODS: We studied cross-sectionally and prospectively (during 24 yr) 9,258 individuals from the Danish general population genotyped for R213G. MEASUREMENTS: We determined plasma extracellular superoxide dismutase concentration, pulmonary function and COPD diagnosed by means of spirometry or through national hospitalization and death registers. MAIN RESULTS: In the general population, 97.5% were noncarriers, 2.4% were heterozygotes, and 0.02% were homozygotes. Among R213G noncarriers, extracellular superoxide dismutase plasma concentration was 148+/-52 and 142+/-43 ng/ml (mean+/-SD) in individuals with and without COPD (Student's t test, p=0.02). Among heterozygotes, corresponding concentrations were 1,665+/-498 ng/ml and 1,256+/-379 (p<0.001). The adjusted odds ratio for spirometrically diagnosed COPD in heterozygotes versus noncarriers was 0.5 (95% confidence interval: 0.3-0.9). After stratification, the equivalent adjusted odds ratio was 1.5 (0.3-6.6) among nonsmokers and 0.4 (0.2-0.8) among smokers (p value for interaction=0.10). The adjusted hazard ratio for COPD hospitalization or death during follow-up in heterozygotes versus noncarriers was 0.3 (0.1-0.8). CONCLUSIONS: Extracellular superoxide dismutase R213G heterozygosity protects against development of COPD in the Danish general population. This was observed in smokers, but not in nonsmokers.

M3 - Journal article

VL - 173

SP - 858

EP - 864

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 8

ER -

ID: 34121183